TRAIL-coated lipid-nanoparticles overcome resistance to soluble recombinant TRAIL in non-small cell lung cancer cells

Nanotechnology

Volumn 27, Issue 18, 2016, Pages

  De Miguel, Diego ^a   Gallego Lleyda, Ana ^a   Ayuso, José María ^a,b   Erviti Ardanaz, Sandra ^a   Pazo Cid, Roberto ^b,c   Del Agua, Celia ^c   Fernández, Luis José ^a,b   Ochoa, Ignacio ^a,b   Anel, Alberto ^a,b   Martinez Lostao, Luis ^a,b,d,e  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b INSTITUTO DE INVESTIGACIÓN SANITARIA ARAGÓN IIS ARAGÓN   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d Instituto de Ciencia de Materiales de Aragón   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

immunotherapy; lipid nanoparticle; liposome; lung cancer; TRAIL; TRAIL resistance

Indexed keywords

BIOLOGICAL ORGANS; CELL CULTURE; CELL DEATH; CYTOLOGY; CYTOTOXICITY; DISEASES; DRUG PRODUCTS; LIPOSOMES; NANOPARTICLES; TUMORS;

ANTI-TUMOR ACTIVITIES; CASPASE-3 ACTIVATION; CYTOTOXIC EFFECTS; IMMUNOTHERAPY; LIPID NANOPARTICLES; LUNG CANCER; NON SMALL CELL LUNG CANCER; TRAIL;

CELLS;

ANTINEOPLASTIC AGENT; CASP3 PROTEIN, HUMAN; CASP8 PROTEIN, HUMAN; CASPASE 3; CASPASE 8; LIPOSOME; NANOPARTICLE; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN; LUNG NEOPLASMS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CASPASE 8; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOSOMES; LUNG NEOPLASMS; NANOPARTICLES; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84962323513     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/27/18/185101     Document Type: Article

References (48)

1. Ashkenazi A 2008 Directing cancer cells to self-destruct with pro-apoptotic receptor agonists Nat. Rev. Drug Discovery 7 1001-12
2. Astashkina A, Mann B and Grainger D W 2012 A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity Pharmacol. Therapeutics 134 82-106
3. Ayuso J M, Monge R, Llamazares G A, Moreno M, Agirregabiria M, Berganzo J, Doblaré M, Ochoa I and Fernández L J 2015 SU-8 based microdevices to study self-induced chemotaxis in 3D microenvironments Front. Mater. 2 37
4. Balsas P, López-Royuela N, Galán-Malo P, Anel A, Marzo I and Naval J 2009 Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis Biochem. Pharmacol. 77 804-12
5. Bernardi S, Secchiero P and Zauli G 2012 State of art and recent developments of anti-cancer strategies based on TRAIL Recent Pat. Anti-Cancer Drug Discov. 7 207-17
6. Cozza G, A Pinna L and Moro S 2013 Kinase CK2 inhibition: An update Curr. Med. Chem. 20 671-93
7. Chen R, Wierda W G, Chubb S, Hawtin R E, Fox J A, Keating M J, Gandhi V and Plunkett W 2009 Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia Blood 113 4637-45
8. De Miguel D, Basanez G, Sanchez D, Malo P G, Marzo I, Larrad L, Naval J, Pardo J, Anel A and Martinez-Lostao L 2013 Liposomes decorated with Apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells Mol. Pharmaceutics 10 893-904
9. De Miguel D, Gallego-Lleyda A, Anel A and Martinez-Lostao L 2015 Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells Leukemia Res. 39 657-66
10. De Miguel D, Gallego-Lleyda A, Galan-Malo P, Rodriguez-Vigil C, Marzo I, Anel A and Martinez-Lostao L 2015 Immunotherapy with liposome-bound TRAIL overcomes partial protection to soluble TRAIL-induced apoptosis offered by down-regulation of Bim in leukemic cells Clin. Transl. Oncol.
11. Feoktistova M, Geserick P, Kellert B, Dimitrova D P, Langlais C, Hupe M, Cain K, MacFarlane M, Hacker G and Leverkus M 2011 cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms Mol. Cell 43 449-63
12. Goodman T T, Ng C P and Pun S H 2008 3D tissue culture systems for the evaluation and optimization of nanoparticle-based drug carriers Bioconjugate Chem. 19 1951-9
13. Greco F A, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G and Klein J 2008 Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer Lung Cancer 61 82-90
14. Herbst R S et al 2010 Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer J. Clin. Oncol. 28 2839-46
15. Hirsch F R, Varella-Garcia M, Bunn P A, Di Maria M V, Veve R, Bremnes R M, Barón A E, Zeng C and Franklin W A 2003 Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis J. Clin. Oncol. 21 3798-807
16. Huang C P, Lu J, Seon H, Lee A P, Flanagan L A, Kim H-Y, Putnam A J and Jeon N L 2009 Engineering microscale cellular niches for three-dimensional multicellular co-cultures Lab Chip 9 1740-8
17. Intemann J, Saidu N E, Schwind L and Montenarh M 2014 ER stress signaling in ARPE-19 cells after inhibition of protein kinase CK2 by CX-4945 Cell. Signalling 26 1567-75
18. Izeradjene K, Douglas L, Delaney A and Houghton J A 2004 Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells Clin. Cancer Res.: Official J. Am. Assoc. Cancer Res. 10 6650-60
19. Izeradjene K, Douglas L, Delaney A and Houghton J A 2005 Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines Oncogene 24 2050-8
20. Koschny R, Ganten T M, Sykora J, Haas T L, Sprick M R, Kolb A, Stremmel W and Walczak H 2007 TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window Hepatology 45 649-58
21. Koschny R et al 2007 Bortezomib sensitizes primary human astrocytoma cells of WHO grades I-IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis Clin. Cancer Res. 13 3403-12
22. Ku M J, Park J W, Ryu B J, Son Y J, Kim S H and Lee S Y 2013 CK2 inhibitor CX4945 induces sequential inactivation of proteins in the signaling pathways related with cell migration and suppresses metastasis of A549 human lung cancer cells Bioorg. Med. Chem. Lett. 23 5609-13
23. Lemke J, von Karstedt S, Abd El Hay M, Conti A, Arce F, Montinaro A, Papenfuss K, El-Bahrawy M A and Walczak H 2014 Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1 Cell Death Differentiation 21 491-502
24. Lemke J, von Karstedt S, Zinngrebe J and Walczak H 2014 Getting TRAIL back on track for cancer therapy Cell Death Differentiation 21 1350-64
25. Martinez-Lorenzo M J, Anel A, Gamen S, Monle N I, Lasierra P, Larrad L, Pineiro A, Alava M A and Naval J 1999 Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles J. Immunol. 163 1274-81
26. Martinez-Lostao L, Garcia-Alvarez F, Basanez G, Alegre-Aguaron E, Desportes P, Larrad L, Naval J, Martinez-Lorenzo M J and Anel A 2010 Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis Arthritis Rheum. 62 2272-82
27. McGrath E E 2011 The tumor necrosis factor-related apoptosis-inducing ligand and lung cancer: Still following the right TRAIL? J. Thoracic Oncol. 6 983-7
28. Micheau O, Shirley S and Dufour F 2013 Death receptors as targets in cancer Br. J. Pharmacol. 169 1723-44
29. Miyashita K, Shiraki K, Fuke H, Inoue T, Yamanaka Y, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K and Nakano T 2006 The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis Int. J. Mol. Med. 18 249-56
30. Monleon I et al 2001 Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells J. Immunol. 167 6736-44
31. Mosmann T 1983 Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays J. Immunol. Methods 65 55-63
32. Navran S 2008 The application of low shear modeled microgravity to 3D cell biology and tissue engineering Biotechnol. Annu. Rev. 14 275-96
33. Nicholson R I, Gee J M W and Harper M E 2001 EGFR and cancer prognosis Eur. J. Cancer 37 9-15
34. Ohsaki Y, Tanno S, Fujita Y, Toyoshima E, Fujiuchi S, Nishigaki Y, Ishida S, Nagase A, Miyokawa N and Hirata S 2000 Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression Oncol. Rep. 7 603-10
35. Palacios C, Yerbes R and Lopez-Rivas A 2006 Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells Cancer Res. 66 8858-69
36. Pitti R M, Marsters S A, Ruppert S, Donahue C J, Moore A and Ashkenazi A 1996 Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family J. Biol. Chem. 271 12687-90
37. Pop C, Oberst A, Drag M, Van Raam B J, Riedl S J, Green D R and Salvesen G S 2011 FLIP(L) induces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity Biochem. J. 433 447-57
38. Pore M M, Hiltermann T J N and Kruyt F A 2013 Targeting apoptosis pathways in lung cancer Cancer Lett. 332 359-68
39. Rosato R R, Almenara J A, Kolla S S, Maggio S C, Coe S, Gimenez M S, Dent P and Grant S 2007 Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions Mol. Cancer Therapeutics 6 692-702
40. Rosato R R, Dai Y, Almenara J A, Maggio S C and Grant S 2004 Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation Leukemia 18 1780-8
41. Siegelin M D 2012 Utilization of the cellular stress response to sensitize cancer cells to TRAIL-mediated apoptosis Expert Opin. Ther. Targets 16 801-17
42. So K S, Rho J K, Choi Y J, Kim S Y, Choi C M, Chun Y J and Lee J C 2015 AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells Anticancer Res. 35 1537-42
43. Soria J C et al 2011 Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer J. Clin. Oncol. 29 4442-51
44. Stegehuis J H, de Wilt L H, de Vries E G, Groen H J, de Jong S and Kruyt F A 2010 TRAIL receptor targeting therapies for non-small cell lung cancer: Current status and perspectives Drug Resist. Updates 13 2-15
45. Wang S and Fischer P M 2008 Cyclin-dependent kinase 9: A key transcriptional regulator and potential drug target in oncology, virology and cardiology Trends Pharmacol. Sci. 29 302-13
46. Weinlich R et al 2013 Protective roles for caspase-8 and cFLIP in adult homeostasis Cell Rep. 5 340-8
47. Wiley S R et al 1995 Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 673-82
48. Yerbes R, Palacios C, Reginato M J and Lopez-Rivas A 2011 Cellular FLIP(L) plays a survival role and regulates morphogenesis in breast epithelial cells Biochim. Biophys. Acta 1813 168-78